Relationship between lymphocyte count, serum zinc and copper during zinc acetate administration in hemodialysis patients with hypozinemia .

Relationship between lymphocyte count, serum zinc and copper during zinc acetate administration in hemodialysis patients with hypozinemia . - Relationship between lymphocyte count, serum zinc and copper

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036716

Enrollment

Registered

2019-06-01

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphopenia in hemodialysis patients

Interventions

Administer 100mg of zinc acetate daily for 12 months to hemodialysis patients with hypozinemia and lymphopenia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hemodialysis patients with serum zinc level less than 65microg/dl before the study

Exclusion criteria

Exclusion criteria: Patients who did not get consent for the trial

Design outcomes

Primary

Measure	Time frame
Increased number of lymphocytes after 12 months by zinc acetate administration	—

Secondary

Measure	Time frame
To evaluate the safety of zinc acetate administration from clinical adverse events and serum zinc and copper levels	—

Countries

Japan

Contacts

Public ContactRYOICHI MIYAZAKI

Fujita Memorial Hospital Internal Medicine

ryoichi@mitene.or.jp0776-21-1277

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026